Halozyme Therapeutics Inc (HALO)vsBeiGene, Ltd. (ONC)
HALO
Halozyme Therapeutics Inc
$107.20
+0.19%
HEALTHCARE · Cap: $12.29B
ONC
BeiGene, Ltd.
$346.51
+1.38%
HEALTHCARE · Cap: $40.53B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 268% more annual revenue ($6.13B vs $1.66B). HALO leads profitability with a 24.9% profit margin vs 10.7%. HALO trades at a lower P/E of 31.9x. HALO earns a higher WallStSmart Score of 72/100 (B).
HALO
Strong Buy72
out of 100
Grade: B
ONC
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for HALO.
Margin of Safety
+80.1%
Fair Value
$1767.21
Current Price
$346.51
$1420.70 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 288 in profit
Strong operational efficiency at 59.8%
Revenue surging 47.7% year-over-year
Keeps 25 of every $100 in revenue as profit
Earnings expanding 42.9% YoY
Earnings expanding 166.7% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Revenue surging 29.6% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Weak financial health signals
Trading at 85.1x book value
Premium valuation, high expectations priced in
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : HALO
The strongest argument for HALO centers on Return on Equity, Operating Margin, Revenue Growth. Profitability is solid with margins at 24.9% and operating margin at 59.8%. Revenue growth of 47.7% demonstrates continued momentum.
Bull Case : ONC
The strongest argument for ONC centers on EPS Growth, Debt/Equity, PEG Ratio. Revenue growth of 29.6% demonstrates continued momentum. PEG of 0.77 suggests the stock is reasonably priced for its growth.
Bear Case : HALO
The primary concerns for HALO are P/E Ratio, Altman Z-Score, Piotroski F-Score. Debt-to-equity of 14.95 is elevated, increasing financial risk.
Bear Case : ONC
The primary concerns for ONC are P/E Ratio, Altman Z-Score. A P/E of 64.1x leaves little room for execution misses.
Key Dynamics to Monitor
HALO carries more volatility with a beta of 0.88 — expect wider price swings.
HALO is growing revenue faster at 47.7% — sustainability is the question.
ONC generates stronger free cash flow (596M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
HALO scores higher overall (72/100 vs 64/100), backed by strong 24.9% margins and 47.7% revenue growth. ONC offers better value entry with a 80.1% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Halozyme Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company is headquartered in San Diego, California.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?